- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03773523
Neuromodulation and Cognitive Training in Opioid Use Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cognitive flexibility, the ability to change maladaptive behavior, depends on dorsolateral prefrontal cortex (DLPFC) input to the nucleus accumbens (NAcc; Gruber, Hussain, and O'Donnell 2009). DLPFC stimulation may increase input to NAcc to facilitate proper selection of goal-directed behavior and may also decrease craving in individuals with substance use disorder (Boggio et al. 2008).
We will use transcranial direct current stimulation (tDCS) to stimulate the DLPFC. TDCS is a non-invasive brain stimulation technique that can modulate brain connectivity. TDCS involves applying a weak electrical current (2mA or less) to the scalp via anodal and cathodal electrode sponges, causing either increases or decreases in cortical excitability, respectively. Research has shown in both healthy subjects and patients (e.g. Alzheimer's disease, Parkinson's disease, stroke, and depression) that tDCS has the potential to modulate synaptic strengthening and neurotransmitter-dependent plasticity underlying changes in behavior and learning (Lang et al. 2005).
We are anticipating enrollment of 30 participants. Fifteen participants will be randomly assigned to the interventional tDCS condition, while 15 participants will be randomly assigned to sham tDCS. Both conditions will undergo five sessions of tDCS across five days. Participants will undergo pre- and post-tDCS MRI scans, in addition to clinical interviews and questionnaires. Follow-up interviews will be conducted in person 1 and 2 months after intervention completion to inquire about relapse status.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jazmin Y Camchong, PhD
- Phone Number: (612) 624-0134
- Email: camch002@umn.edu
Study Contact Backup
- Name: Lamisa N Chowdhury, BS
- Phone Number: (612) 626-6808
- Email: chow0082@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- Recruiting
- University of Minnesota
-
Sub-Investigator:
- Kelvin O Lim, MD
-
Contact:
- Jazmin Y Camchong, PhD
- Phone Number: 612-624-0134
- Email: camch002@umn.edu
-
Principal Investigator:
- Jazmin Y Camchong, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 20 abstinent individuals (18-60 years old; 1-2 weeks of abstinence) who meet DSM-V criteria for opioid use disorder (OUD) will be recruited from the Lodging Plus Program, part of University of Minnesota Medical Center
- This 28-day program provides a supervised environment to treat individuals with OUD in which patients receive random drug screenings. Lodging Plus has 50 beds and admits an average of 20 patients per week and about 50% of patients admitted have a diagnosis of opioid use disorder.
- Ability to provide written consent and comply with study procedures, meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnostic criteria for OUD. Subjects may have current comorbid drug use, but their primary substance use disorder diagnosis needs to be based on opioid use. Subjects must have the intention to remain in the Lodging Plus program (4 weeks) until the end of the intervention portion of the study. Vulnerable populations will not be included.
Exclusion Criteria:
- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness>30 min, HIV)
- A head injury resulting in a skull fracture or a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
- Any contraindications for tDCS or MRI scanning (tDCS contraindication: history of seizures; MRI contraindications; metal implants, pacemakers or any other implanted electrical device, injury with metal, braces, dental implants, non-removable body piercings, pregnancy, breathing or moving disorder)
- DSM-V criteria for psychiatric disorder, may have a lifetime diagnosis of depression
- Presence of a condition that would render study measures difficult or impossible to administer or interpret
- Age outside the range of 18 to 60
- Primary current substance use disorder diagnosis on a substance other than opioid except for caffeine or nicotine
- Clinical evidence for Wernicke-Korsakoff syndrome
- Nicotine use will be recorded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: active tDCS
Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
|
tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA.
This study is regulated by the FDA as an Abbreviated IDE.
It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable.
The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes.
These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008).
No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007).
Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
Other Names:
|
Sham Comparator: Sham Comparator: sham tDCS
Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
There will be a total of 5 sham tDCS sessions.
|
tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA.
This study is regulated by the FDA as an Abbreviated IDE.
It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable.
The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes.
These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008).
No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007).
Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in brain functional connectivity as measured by functional magnetic resonance imaging
Time Frame: Change between baseline and 1-week follow-up
|
Investigators will measure magnitude of functional connectivity in between nucleus accumbens (NAcc) and prefrontal cortex (PFC) both at baseline and at follow-up and compare the magnitude of change between the active-tDCS and sham-tDCS groups.
|
Change between baseline and 1-week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between functional connectivity change and craving scores
Time Frame: Data collection will be during 2 and 3 weeks of abstinence
|
Investigators will (1) compare change in craving scores (difference in craving scores between 2 and 3 weeks of abstinence) between active-tDCS and sham-tDCS groups and (2) conduct parametric correlations between functional connectivity change and change in craving scores.
|
Data collection will be during 2 and 3 weeks of abstinence
|
Correlation between functional connectivity change and clinical outcome
Time Frame: Between 2 weeks of abstinence and 2 months later
|
Investigators will record relapse status during the 2 months following treatment discharge.
|
Between 2 weeks of abstinence and 2 months later
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kelvin O Lim, MD, University of Minnesota
- Principal Investigator: Jazmin Y Camchong, PhD, University of Minnesota
Publications and helpful links
General Publications
- Camchong J, Macdonald AW 3rd, Mueller BA, Nelson B, Specker S, Slaymaker V, Lim KO. Changes in resting functional connectivity during abstinence in stimulant use disorder: a preliminary comparison of relapsers and abstainers. Drug Alcohol Depend. 2014 Jun 1;139:145-51. doi: 10.1016/j.drugalcdep.2014.03.024. Epub 2014 Mar 29.
- Camchong J, Stenger A, Fein G. Resting-state synchrony during early alcohol abstinence can predict subsequent relapse. Cereb Cortex. 2013 Sep;23(9):2086-99. doi: 10.1093/cercor/bhs190. Epub 2012 Jul 20.
- Camchong J, Stenger VA, Fein G. Resting-state synchrony in short-term versus long-term abstinent alcoholics. Alcohol Clin Exp Res. 2013 May;37(5):794-803. doi: 10.1111/acer.12037. Epub 2013 Feb 19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSYCH-2018-27116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Dependence
-
National Development and Research Institutes, Inc.Unknown
-
MindLight, LLCMclean HospitalRecruitingOpioid Dependence | Opioid Use | Opioid Abuse | Opiate Dependence | Opioid Use, Unspecified | Opioid Use Disorder, ModerateUnited States
-
Milton S. Hershey Medical CenterRecruitingOpioid Dependence FentanylUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)Completed
-
Orexo ABWorldwide Clinical TrialsCompletedOpioid Dependence, on Agonist TherapyUnited States
-
National Development and Research Institutes, Inc.St. Luke's-Roosevelt Hospital CenterUnknownOpioid-Dependence Among AdolescentsUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)CompletedOpioid Dependence | Opioid-use Disorder | Opiate DependenceUnited States
-
Orexo ABWorldwide Clinical TrialsCompletedOpioid Dependence, on Agonist TherapyUnited States
-
Indivior Inc.CompletedOpioid Dependence | Cocaine Dependence | Opioid Related DisordersUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Completed
Clinical Trials on Transcranial Direct Current Stimulation (tDCS)
-
Manhattan Psychiatric CenterCompletedSchizophrenia | Auditory HallucinationUnited States
-
Charite University, Berlin, GermanyTerminatedNeuralgia | Neuropathic PainGermany
-
D'Or Institute for Research and EducationCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
Massachusetts General HospitalRecruitingAttention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
Oslo University HospitalCompleted
-
Hospital de Clinicas de Porto AlegreUnknownChronic Pain | EndometriosisBrazil
-
The National Brain Mapping Laboratory (NBML)Neuroelectrics Corporation; Leibniz-Institut für Arbeitsforschung; Zanjan University...CompletedDepressive Disorder | Cognitive Impairment | Psychiatric DisorderIran, Islamic Republic of
-
Pusan National University Yangsan HospitalRecruiting
-
VA Office of Research and DevelopmentRecruitingSuicide | ImpulsivityUnited States
-
VA Office of Research and DevelopmentRecruitingObesityUnited States